# Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours

Source: https://onco.cc/trials/nct07446855/  
OnCo record `nct07446855` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is recruiting.

## Summary

The registry lists NCT07446855 as recruiting, last updated 2026-10-01. Enrolment is 180 planned participants, an estimate. Interventions: AZD4956, Saruparib. Primary measures include Parts A and B: Number of participants with adverse events (AEs) and serious adverse events (SAEs); Part B: Progression free survival (PFS). No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Also known as: PARTHENON
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07446855
- Phase: 1/2
- Setting: A Modular Open-label, Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Ascending Doses of AZD4956 as Monotherapy, and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Repair Defective Solid Tumours
- Sponsor: AstraZeneca

## Sources

- ClinicalTrials.gov NCT07446855: https://clinicaltrials.gov/study/NCT07446855

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [Saruparib](https://onco.cc/drugs/saruparib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct07446855.json